<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02735707</url>
  </required_header>
  <id_info>
    <org_study_id>REMAP-CAP</org_study_id>
    <secondary_id>2015-002340-14</secondary_id>
    <secondary_id>602525</secondary_id>
    <nct_id>NCT02735707</nct_id>
  </id_info>
  <brief_title>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia</brief_title>
  <acronym>REMAP-CAP</acronym>
  <official_title>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators aim to build an infrastructure for rapidly obtaining
      evidence for the management of patients requiring admission to an ICU during a pandemic of
      severe respiratory infections. Furthermore, during the inter-pandemic phase, this
      infrastructure will consist of a rolling adaptive clinical trial evaluating different
      management strategies of patients with severe CAP admitted to ICU. This ongoing trial will
      serve as the framework in which different aspects of ICU patient management can be rigorously
      and rapidly evaluated through rapid modification (adaptation) of the trial interventions
      based on new circumstances (e.g., a pandemic). These modifications or adaptations may include
      adding &quot;pandemic&quot; study arms (with or without predefined treatment) or changing randomization
      schemes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality (%) measured at day 60 after randomization of the patients included in this trial.</measure>
    <time_frame>60 days</time_frame>
    <description>Mortality (%) measured at day 60 after randomization of the patients included in this trial for all different interventions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay of the patients included in this trial.</measure>
    <time_frame>Through study completion, average of 6 days</time_frame>
    <description>ICU length of stay of the patients included in this trial, measured in number of days for all interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay of the patients included in this trial.</measure>
    <time_frame>Through study completion, average of 10 days</time_frame>
    <description>Hospital length of stay of the patients included in this trial, measured in number of days for all interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days.</measure>
    <time_frame>Day 30</time_frame>
    <description>Measure the number of ventilator free days of the patients included in this trial at day 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days.</measure>
    <time_frame>Day 60</time_frame>
    <description>Measure the number of ventilator free days of the patients included in this trial at day 60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ failure free days.</measure>
    <time_frame>Day 30</time_frame>
    <description>Measure the number of organ failure free days of the patients included in this trial at day 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ failure free days.</measure>
    <time_frame>Day 60</time_frame>
    <description>Measure the number of organ failure free days of the patients included in this trial at day 60.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Community Acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Antibiotic A, no steroid, min dist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cephalosporin according to local guidelines plus macrolide for at least 7 days + no hydrocortisone for 7 days + invasive mechanical ventilation with &quot;minimal distension&quot; strategy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic A, no steroid, max recruit</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cephalosporin according to local guidelines plus macrolide for at least 7 days + no hydrocortisone for 7 days + invasive mechanical ventilation with &quot;maximal recruitment strategy&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic A, no steroid, ECCO2R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cephalosporin according to local guidelines plus macrolide for at least 7 days + no hydrocortisone for 7 days + invasive mechanical ventilation with ECCO2R device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic A, steroid, min dist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cephalosporin according to local guidelines plus macrolide for at least 7 days + hydrocortisone for 7 days + invasive mechanical ventilation with &quot;minimal distension&quot; strategy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic A, steroid, max recruit</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cephalosporin according to local guidelines plus macrolide for at least 7 days + hydrocortisone for 7 days + invasive mechanical ventilation with &quot;maximal recruitment strategy&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic A, steroid, ECCO2R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cephalosporin according to local guidelines plus macrolide for at least 7 days + hydrocortisone for 7 days + invasive mechanical ventilation with ECCO2R device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic B, no steroid, min dist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Respiratory quinolon for at least 7 days + no hydrocortisone for 7 days + invasive mechanical ventilation with &quot;minimal distension&quot; strategy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic B, no steroid, max recruit</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Respiratory quinolon for at least 7 days + no hydrocortisone for 7 days + invasive mechanical ventilation with &quot;maximal recruitment strategy&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic B, no steroid, ECCO2R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Respiratory quinolon for at least 7 days + no hydrocortisone for 7 days + invasive mechanical ventilation with ECCO2R device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic B, steroid, min dist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Respiratory quinolon for at least 7 days + hydrocortisone for 7 days + invasive mechanical ventilation with &quot;minimal distension&quot; strategy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic B, steroid, max recruit</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Respiratory quinolon for at least 7 days + hydrocortisone for 7 days + invasive mechanical ventilation with &quot;maximal recruitment strategy&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic B, steroid, ECCO2R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Respiratory quinolon for at least 7 days + hydrocortisone for 7 days + invasive mechanical ventilation with ECCO2R device</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic A</intervention_name>
    <description>Comparison of 3rd generation cephalosporins plus macrolide versus a respiratory quinolone.</description>
    <arm_group_label>Antibiotic A, no steroid, min dist</arm_group_label>
    <arm_group_label>Antibiotic A, no steroid, max recruit</arm_group_label>
    <arm_group_label>Antibiotic A, no steroid, ECCO2R</arm_group_label>
    <arm_group_label>Antibiotic A, steroid, min dist</arm_group_label>
    <arm_group_label>Antibiotic A, steroid, max recruit</arm_group_label>
    <arm_group_label>Antibiotic A, steroid, ECCO2R</arm_group_label>
    <other_name>Cefotaxim</other_name>
    <other_name>Ceftriaxone</other_name>
    <other_name>Azitromycin</other_name>
    <other_name>Claritromycin</other_name>
    <other_name>Erytromycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic B</intervention_name>
    <description>Comparison of 3rd generation cephalosporins plus macrolide versus a respiratory quinolone.</description>
    <arm_group_label>Antibiotic B, no steroid, min dist</arm_group_label>
    <arm_group_label>Antibiotic B, no steroid, max recruit</arm_group_label>
    <arm_group_label>Antibiotic B, no steroid, ECCO2R</arm_group_label>
    <arm_group_label>Antibiotic B, steroid, min dist</arm_group_label>
    <arm_group_label>Antibiotic B, steroid, max recruit</arm_group_label>
    <arm_group_label>Antibiotic B, steroid, ECCO2R</arm_group_label>
    <other_name>Moxifloxacin</other_name>
    <other_name>Levofloxacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Hydrocortison 100 mg iv every 8 hours for 7 days versus no hydrocortisone</description>
    <arm_group_label>Antibiotic A, steroid, min dist</arm_group_label>
    <arm_group_label>Antibiotic A, steroid, max recruit</arm_group_label>
    <arm_group_label>Antibiotic A, steroid, ECCO2R</arm_group_label>
    <arm_group_label>Antibiotic B, steroid, min dist</arm_group_label>
    <arm_group_label>Antibiotic B, steroid, max recruit</arm_group_label>
    <arm_group_label>Antibiotic B, steroid, ECCO2R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Minimal distension</intervention_name>
    <description>Comparison of &quot;minimal distension&quot; strategy versus &quot;maximal recruitment&quot; strategy. A third comparison (only in selected sites) is &quot;ultra-protective with maximum of 4 ml/kg ventilation plus ECCO2R.</description>
    <arm_group_label>Antibiotic A, no steroid, min dist</arm_group_label>
    <arm_group_label>Antibiotic A, steroid, min dist</arm_group_label>
    <arm_group_label>Antibiotic B, no steroid, min dist</arm_group_label>
    <arm_group_label>Antibiotic B, steroid, min dist</arm_group_label>
    <other_name>Mechanical ventilator with low PEEP settings</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Maximal recruitment</intervention_name>
    <description>Comparison of &quot;minimal distension&quot; strategy versus &quot;maximal recruitment&quot; strategy. A third comparison (only in selected sites) is &quot;ultra-protective with maximum of 4 ml/kg ventilation plus ECCO2R.</description>
    <arm_group_label>Antibiotic A, no steroid, max recruit</arm_group_label>
    <arm_group_label>Antibiotic A, steroid, max recruit</arm_group_label>
    <arm_group_label>Antibiotic B, no steroid, max recruit</arm_group_label>
    <arm_group_label>Antibiotic B, steroid, max recruit</arm_group_label>
    <other_name>Mechanical ventilator with high PEEP settings</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ECCO2R</intervention_name>
    <description>Comparison of &quot;minimal distension&quot; strategy versus &quot;maximal recruitment&quot; strategy. A third comparison (only in selected sites) is &quot;ultra-protective with maximum of 4 ml/kg ventilation plus ECCO2R.</description>
    <arm_group_label>Antibiotic A, no steroid, ECCO2R</arm_group_label>
    <arm_group_label>Antibiotic A, steroid, ECCO2R</arm_group_label>
    <arm_group_label>Antibiotic B, no steroid, ECCO2R</arm_group_label>
    <arm_group_label>Antibiotic B, steroid, ECCO2R</arm_group_label>
    <other_name>PALP</other_name>
    <other_name>Novalung</other_name>
    <other_name>Alung</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - The trial participants are patients with severe CAP that are admitted to an ICU as part
        of their routine clinical care.

        Overall Platform Inclusion Criteria

        In order to be eligible to participate in this study, a patient must meet all five of the
        following criteria:

          1. Admitted to ICU within 48hrs of hospitalisation

          2. ≥18 years of age

          3. Suspected of community-acquired pneumonia:

               -  i) onset of symptoms outside the hospital or long term care facility;

               -  ii) Pneumonia is considered the primary admission diagnosis.

             Exclusion Criteria:

             Overall Platform Exclusion Criteria

             A potential eligible patient who meets any of the following criteria will be excluded
             from participation in this study:

             • Recent institutional exposure within 30 days of presentation to the hospital (to
             exclude healthcare-associated pneumonia)

             • Resident of nursing home or long term care facility.

             • No commitment to aggressive care; treatment is not aimed at recovery of the patient.

             • Significant trauma, burns

             • On ECMO (Extra Corporal Membrane Oxygenation)

             • Severe chronic liver disease (Child-Pugh class C)

               -  Bone marrow transplant or chemotherapy-induced neutropenia.

               -  Participation in a competing interventional study (see below 7.5).

             Additional Antibiotic Domain Exclusion criteria

             • Known allergy to one of the study drugs.

             Additional Steroid/Immunomodulatory Domain Exclusion criteria • Patient has received
             &gt;24 hours of steroid treatment at an immunomodulatory dose (defined as more than 25mg
             of hydrocortisone, more than 5 mg prednisone or more than 1 mg dexamethasone per 24
             hours) prior to randomisation.

             Additional General Ventilatory Domain Inclusion criteria • Intubated within 72 hours
             of ICU admission;

             • Presence of bilateral alveolar infiltrates on chest X-ray;

             • Moderate to severe ARDS oxygenation criteria (PaO2/FiO2 ratio &lt;200mmHg) on a PEEP of
             5cmH2O

             Additional Specific Ventilatory Domain Exclusion Criteria

               -  No longer than 48 hours of tracheal intubation and ventilation before
                  randomization;

               -  Barotrauma (pneumothorax, pneumomediastinum, subcutaneous emphysema or the
                  presence of any intercostal catheter),

               -  Contraindication for siting of ECCO2R cannulae (ECCO2R arm only)

             Study subjects may be co-enrolled in other research studies when such co-enrolment
             does not threaten the validity of either study or substantively increase the risk to
             the study subjects. Approval of co-enrolment with interventional studies will be
             determined on a case-by-case basis by the study management team.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Bonten, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Bonten, Prof.</last_name>
    <phone>+31 (0) 88 75 573 94</phone>
    <email>M.J.M.Bonten@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lennie Derde, MD</last_name>
    <phone>+31 (0) 88 755 5555</phone>
    <email>L.P.G.Derde@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Antwerp</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Herman Goossens, Prof</last_name>
      <phone>+32 3 821 37 89</phone>
      <email>Herman.Goossens@uza.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <state>Paris Cedex 14</state>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Daniel Chiche, Prof</last_name>
      <phone>+33 (0) 158412739 (ICU)</phone>
      <email>jean-daniel.chiche@cch.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tobias Welte, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College Dublin</name>
      <address>
        <city>Dublin</city>
        <state>Dublin 4</state>
        <zip>D04 V1W8</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alistair Nichol, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMCU Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Bonten, Prof</last_name>
      <phone>+31 88 75 573 94</phone>
      <email>M.J.M.Bonten@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lennie Derde, MD</last_name>
      <phone>+31 (0)88 755 5555</phone>
      <email>L.P.G.Derde@umcutrecht.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.prepare-europe.eu/</url>
    <description>Homepage PREPARE (Platform foR European Preparedness Against (Re-)emerging Epidemics)</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2015</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>MJM Bonten</investigator_full_name>
    <investigator_title>Prof. Medical Microbiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

